Blood TransfusionCoBAnKNCT06142825
Developing, Implementing and Evaluating Effective Community-facility Interactions to Improve Blood Availability and Transfusion in Three Distinct County Settings in Kenya
A study testing Community-Facility Transfusion Committee (CFTC) in people with Blood Transfusion, run by University of Minnesota at 1 site in United States.
Trial summary
The strategy of the CoBAnK study is to establish and enable the function of Community-Facility Transfusion Committees (CFTCs) incorporating diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Blood Transfusion
- What is being tested?
- Community-Facility Transfusion Committee (CFTC)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 9 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Mar 2025to 11 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Eligibility criteria for study sites (beta hospitals):
- Transfusing hospital at level 3 or higher
- Has conducted at least 20 blood transfusions in the preceding year
- Does not have a KTTA-approved blood bank (regional or satellite) in the facility premises
- Receives blood from a blood bank at an Alpha Facility in the same county
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Minnesota
Minneapolis, Minnesota, 55414
About this study
Official title: Developing, Implementing and Evaluating Effective Community-facility Interactions to Improve Blood Availability and Transfusion in Three Distinct County Settings in Kenya (CoBAnK): A Type III Hybrid Effectiveness-implementation Trial.
The strategy of the CoBAnK study is to establish and enable the function of Community-Facility Transfusion Committees (CFTCs) incorporating diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care.
Read the detailed description
The strategy of the CoBAnK study is to establish and enable the function of Community-Facility Transfusion Committees (CFTCs) incorporating diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care. The CFTC strategy will be evaluated across nine transfusing facilities across three counties in Kenya (two intervention and one control site in each county). While the intervention will be tested in "beta" facilities (i.e., facilities without a co-located blood bank) in each county, blood availability will also be measured in "alpha" facilities (i.e., facilities with co-located blood banks) in the three counties, which supply blood to the beta facilities.
- Conditions
- Blood Transfusion
- Being tested
- Community-Facility Transfusion Committee (CFTC)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Community-Facility Transfusion Committee (CFTC)Other
Community-Facility Transfusion Committees (CFTCs) are intended to incorporate diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care.
| Study group | Role | What they receive |
|---|---|---|
| CFTC | Experimental | Community-Facility Transfusion Committees (CFTCs) will be established at the facilities randomized to this arm. Receives: Other: Community-Facility Transfusion Committee (CFTC) |
| Control | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Met blood need
The proportion of transfusion requests resulting in dispatch of blood products from the laboratory
Measured: The time required for the hospital laboratory to process a request for blood for transfusion, up to two weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Nov 2023
- Study start11 Mar 2025
- Primary completion11 Jun 2026
- Study completion11 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Blood TransfusionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Type III hybrid effectiveness-implementation trial
- Masking
- None (open label)
- Enrolment
- 9 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Minnesota
- Sponsor type
- University, hospital or other
- Collaborators
- Strathmore University, University of Pittsburgh, Center for Public Health and Development, Kenya (CPHD), National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06142825
- Sponsor's protocol ID
- B09
- Other IDs
- 5UH3HL151595-04
- Acronym
- CoBAnK
- Status last verified
- Jun 2026
- First submitted
- 15 Nov 2023
- Last updated
- 18 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The BLOODSAFE project is committed to quickly sharing results and data. Papers will be submitted summarizing the primary results of the BLOODSAFE studies once the analysis is complete. These results will be published in major scientific journals and presented at scientific meetings.
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Developing, Implementing and Evaluating Effective Community-facility Interactions to Improve Blood Availability and Transfusion in Three Distinct County Settings in Kenya (CoBAnK): A Type III Hybrid Effectiveness-implementation Trial.
- ClinicalTrials.gov ID
- NCT06142825
- Acronym / sponsor ID
- CoBAnK / B09
- Conditions
- Blood Transfusion
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 9 participants (actual)
- Lead sponsor
- University of MinnesotaUniversity, hospital or other
- Collaborators
- Strathmore University, University of Pittsburgh, Center for Public Health and Development, Kenya (CPHD), National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- 11 Mar 2025 (actual)
- Primary completion
- 11 Jun 2026 (actual)
- Study completion
- 11 Jun 2026 (actual)
- First posted
- 22 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The strategy of the CoBAnK study is to establish and enable the function of Community-Facility Transfusion Committees (CFTCs) incorporating diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care.
Detailed description
The strategy of the CoBAnK study is to establish and enable the function of Community-Facility Transfusion Committees (CFTCs) incorporating diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care. The CFTC strategy will be evaluated across nine transfusing facilities across three counties in Kenya (two intervention and one control site in each county). While the intervention will be tested in "beta" facilities (i.e., facilities without a co-located blood bank) in each county, blood availability will also be measured in "alpha" facilities (i.e., facilities with co-located blood banks) in the three counties, which supply blood to the beta facilities.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Type III hybrid effectiveness-implementation trial
| Arm | Type | Receives |
|---|---|---|
| CFTC | Experimental | Other: Community-Facility Transfusion Committee (CFTC)Community-Facility Transfusion Committees (CFTCs) will be established at the facilities randomized to this arm. |
| Control | No intervention | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Community-Facility Transfusion Committee (CFTC)Community-Facility Transfusion Committees (CFTCs) are intended to incorporate diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care. | Other | CFTC |
Primary outcome
Met blood need
Time frame: The time required for the hospital laboratory to process a request for blood for transfusion, up to two weeks.
The proportion of transfusion requests resulting in dispatch of blood products from the laboratory
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2026.
- Individual participant dataSharing planned: No. The BLOODSAFE project is committed to quickly sharing results and data. Papers will be submitted summarizing the primary results of the BLOODSAFE studies once the analysis is complete. These results will be published in major scientific journals and presented at scientific meetings.
Related trials for Blood Transfusion
RecruitingPhase 3
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Myelodysplastic Syndromes
Recruiting
Blood Transfusion Strategies During Major Surgery
Perioperative Red Blood Cell Transfusion
RecruitingObservational study
The Correlation Between Red Cell Transfusion and Complications of Prematurity
Retinopathy of Prematurity (ROP), Bronchopulmonary Dysplasia (BPD)
RecruitingObservational study
Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia
Thrombocytopenia, Platelet Transfusion
Not yet recruitingObservational study
Patient Blood Management in Obstetrics
Patient Blood Management, Blood Product Transfusion for All Conditions
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Community-Facility Transfusion Committee (CFTC) in people with Blood Transfusion, run by University of Minnesota at 1 site in United States.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Met blood need (time frame: The time required for the hospital laboratory to process a request for blood for transfusion, up to two weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026.